GlobeNewswire

Nominating committee ahead of Industrivärden’s 2021 AGM

Share

In accordance with a resolution for the Nominating Committee made by the 2011 Annual General Meeting, and which applies until further notice, the Chairman of the Board is assigned the task of contacting four shareholders from among the largest registered shareholders in terms of votes in Euroclear Sweden AB's printout of the shareholder register as per the last business day in August, who each appoints one representative who is not a director on the Company's board, to form together with the Chairman of the Board a Nominating Committee for the time until a new Nominating Committee has been appointed. The Nominating Committee appoints a committee chair from among its members. The composition of the Nominating Committee shall be made public not later than six months before the next Annual General Meeting. No fee is payable for work on the Nominating Committee.

Accordingly, the Nominating Committee has the following composition: Mats Guldbrand, L E Lundbergföretagen, Stefan Nilsson, Handelsbanken Pension Foundation and others, Mikael Schmidt, SCA and Essiy Pension Foundations and others, Bo Damberg, Jan Wallanders and Tom Hedelius Foundation and others, and Fredrik Lundberg, Chairman of the Board of Industrivärden.

If a member leaves the Nominating Committee before its work has been completed, and if the Nominating Committee is of the opinion that there is a need to replace the said member, the Nominating Committee shall appoint a new member. Any change in the Nominating Committee's composition shall be announced immediately.

Industrivärden’s Annual General Meeting will be held in the Vinterträdgården room at the Grand Hôtel, Stockholm, at 2 p.m. on April 21, 2021.        


Stockholm, September 25, 2020

AB INDUSTRIVÄRDEN (publ)


For further information, please contact:

Fredrik Lundberg, Convening member of Nominating Committee, tel. +48-8-463 06 00.


The information was submitted for publication by the Head of Corporate Communications, Sverker Sivall (tel. +46-8-666 64 00), at 10:00 a.m. CET on September 25, 2020.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AML30.11.2020 16:31:31 CETPress release

STOCKHOLM, SWEDEN – November 30, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML). The company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes (MDS). The FDA’s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditions and address an unmet medical need. A drug candidate that receives Fast Track designation may be eligible for more frequent interaction with the FDA to discuss the drug candidate’s development plan as well as eligibility for accelerated approval and priority review. Eprenetapopt (APR-246) is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein by restori

Karolinska Developments portföljbolag Aprea Therapeutics erhåller Fast Track designation från FDA för behandling med eprenetapopt vid AML30.11.2020 16:31:31 CETPressemelding

STOCKHOLM, SVERIGE 30 november 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat Fast Track designation för portföljbolaget Aprea Therapeutics läkemedelskandidat eprenetapopt vid behandling av TP53-mutant akut myeloisk leukemi (AML). Bolaget har tidigare erhållit Breakthrough-status, särläkemedelsstatus och Fast Track designation för eprenetapopt vid behandling av TP53-mutant myelodysplastiskt syndrom (MDS). FDA:s Fast Track designation är avsedd att underlätta utvecklingen och den regulatoriska granskningen av läkemedelskandidater som adresserar allvarliga sjukdomstillstånd och tillgodoser betydande medicinska behov. En läkemedelskandidat som erhåller Fast Track designation kan vara berättigad till frekventare interaktion med FDA för att diskutera den fortsatta utvecklingsplanen och ger dessutom möjlighet till påskyndad handläggning av en registreringsansökan. Eprenetapopt (APR-246) är en småmolekylär läke

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER30.11.2020 16:20:00 CETPress release

Complete terms and conditions can be retrieved at http://www.riksbank.se https://www.riksbank.se/sv/penningpolitik/penningpolitiska-instrument/kop-av-foretagscertifikat/ Bid procedure, 2020-12-02CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the latest maturity date as of 2021-06-02 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2020-11-23 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2020-12-02Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid vol

Olainfarm Group maintains its profit forecast, a short term decline in 9 month sales results30.11.2020 15:59:00 CETPress release

In 2020, the Olainfarm Group continued its ongoing activity in major sales markets. The highest sales in nine months in 2020 was in Latvia, reaching 28 738 thousand EUR, which is 232 thousand EUR or 1% higher than the same period year ago. Latvia sales represent 32% in Group revenues. Sales in Russia for the nine months period in 2020 amount to 20 590 thousand EUR which is a decrease from 2019 due to extra one-off shipment at the end of 2019 for consumption in the first quarter 2020 amounting to 6 million EUR. “Covid-19 pandemic and restrictions due to it have brought different challenges our way, but we understand how to tackle them, and are committed to reach our growth plans outlined in the company's 5-year strategy. As a long-term investment, we have established a subsidiary in Russia, which allows us to get insights from the medical community and market research so that our efforts are relevant and current to customer needs. I am happy to announce that the new business model in Ru

Kommuniké från extra bolagsstämma i Active Biotech samt justering av tidigare kommunicerad tidplan avseende nyemissionen30.11.2020 15:30:00 CETPressemelding

Extra bolagsstämma i Active Biotech AB (publ) hölls den 30 november 2020. Stämman beslutade, i enlighet med styrelsens förslag, om nyemission med företrädesrätt för aktieägarna. Genom nyemissionen ges högst 72 618 240 nya aktier ut. Två befintliga aktier berättigar till teckning av en ny aktie. Nyemissionen omfattas av vederlagsfria teckningsåtaganden och emissionsgarantier om cirka 40,0 miljoner kronor. Teckningskursen uppgår till 1,05 kronor per aktie. Avstämningsdag för rätt att delta i nyemissionen är den 4 januari 2021. Teckning av de nya aktierna ska ske under perioden 7 – 21 januari 2021. Ett prospekt avseende nyemissionen kommer att offentliggöras före teckningsperiodens början. Preliminär tidplan Sista dag för handel i Active Biotech-aktien inklusive rätt att delta i emissionen infaller den 29 december 2020, istället för den 30 december 2020 som tidigare har kommunicerats. 30 november 2020Extra bolagsstämma 29 december 2020Sista dag för handel i Active Biotech-aktien inklusive